Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

Lemzinc - Philippines FDA Drug Approval Details

Approvals/Philippines FDA/Lemzinc

Approved

STANDARD

Lemzinc

Diamond Laboratories Inc.🇵🇭 Food and Drug Administration - Philippines

Approval Date: Jul 14, 2025
Approval ID: be1d1be832ff90af
Company: Diamond Laboratories Inc.
Type: Standard

Approval Details

Approval Id: be1d1be832ff90af
Drug Approval Philippines Name: Lemzinc
Product Name: Lemzinc
Registration Number: DRP-7223
Brand Name: Lemzinc
Generic Name: Zinc Sulfate Monohydrate
Dosage Form: Syrup (Oral Drops)
Dosage Strength: 27.5mg/mL (Equi. To 10mg elemental Zinc
Manufacturer: Diamond Laboratories Inc.
Distributor: Rilem Pharma Corp.
Issuance Date: 24 January 2025
Expiry Date: 20 April 2030
Pharmacologic Category: Mineral
Classification: Over-the-Counter (OTC)

Active Ingredients

Approved

Quick Info

Agency

Philippines FDA

Country

🇵🇭

Approval Date

Jul 14, 2025

Approval ID

be1d1be832ff90af

Type

Standard

Back to Philippines FDA Approvals